ぶどう膜黒色腫(Uveal Melanoma)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Uveal Melanoma Overview 7
Therapeutics Development 8
Pipeline Products for Uveal Melanoma – Overview 8
Pipeline Products for Uveal Melanoma – Comparative Analysis 9
Uveal Melanoma – Therapeutics under Development by Companies 10
Uveal Melanoma – Therapeutics under Investigation by Universities/Institutes 11
Uveal Melanoma – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Uveal Melanoma – Products under Development by Companies 15
Uveal Melanoma – Products under Investigation by Universities/Institutes 16
Uveal Melanoma – Companies Involved in Therapeutics Development 17
Array BioPharma Inc. 17
AstraZeneca PLC 18
Celldex Therapeutics, Inc. 19
Eli Lilly and Company 20
GlaxoSmithKline plc 21
Novartis AG 22
Pfizer Inc. 23
Spectrum Pharmaceuticals, Inc. 24
Uveal Melanoma – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
binimetinib – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
crizotinib – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Dendritic Cell Therapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
emibetuzumab – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
glembatumumab vedotin – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
merestinib – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
nutlin-3 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
pasireotide LAR – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
selumetinib sulfate – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
sotrastaurin acetate – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
sunitinib malate – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
trametinib dimethyl sulfoxide + uprosertib – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
vincristine sulfate – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Uveal Melanoma – Recent Pipeline Updates 65
Uveal Melanoma – Dormant Projects 83
Uveal Melanoma – Product Development Milestones 84
Featured News & Press Releases 84
Jun 01, 2013: AstraZeneca’s New Therapy Selumetinib Improves Progression-Free Survival And Shrink Tumors In Metastatic Uveal Melanoma, Researchers Report 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86